vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and WORKIVA INC (WK). Click either name above to swap in a different company.
WORKIVA INC is the larger business by last-quarter revenue ($238.9M vs $183.1M, roughly 1.3× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 4.9%, a 8.4% gap on every dollar of revenue. On growth, WORKIVA INC posted the faster year-over-year revenue change (19.5% vs -1.8%). WORKIVA INC produced more free cash flow last quarter ($50.7M vs $24.6M). Over the past eight quarters, WORKIVA INC's revenue compounded faster (16.6% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Workiva, Inc. is a global software-as-a-service (SaaS) company. It provides a cloud-based connected and reporting compliance platform that enables the use of connected data and automation of reporting across finance, accounting, risk, and compliance.
AMPH vs WK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $238.9M |
| Net Profit | $24.4M | $11.8M |
| Gross Margin | 46.8% | 80.7% |
| Operating Margin | 19.4% | 3.3% |
| Net Margin | 13.3% | 4.9% |
| Revenue YoY | -1.8% | 19.5% |
| Net Profit YoY | -35.7% | 234.0% |
| EPS (diluted) | $0.51 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $238.9M | ||
| Q3 25 | $191.8M | $224.2M | ||
| Q2 25 | $174.4M | $215.2M | ||
| Q1 25 | $170.5M | $206.3M | ||
| Q4 24 | $186.5M | $199.9M | ||
| Q3 24 | $191.2M | $185.6M | ||
| Q2 24 | $182.4M | $177.5M | ||
| Q1 24 | $171.8M | $175.7M |
| Q4 25 | $24.4M | $11.8M | ||
| Q3 25 | $17.4M | $2.8M | ||
| Q2 25 | $31.0M | $-19.4M | ||
| Q1 25 | $25.3M | $-21.4M | ||
| Q4 24 | $38.0M | $-8.8M | ||
| Q3 24 | $40.4M | $-17.0M | ||
| Q2 24 | $37.9M | $-17.5M | ||
| Q1 24 | $43.2M | $-11.7M |
| Q4 25 | 46.8% | 80.7% | ||
| Q3 25 | 51.4% | 79.3% | ||
| Q2 25 | 49.6% | 77.0% | ||
| Q1 25 | 50.0% | 76.6% | ||
| Q4 24 | 46.5% | 77.1% | ||
| Q3 24 | 53.3% | 76.5% | ||
| Q2 24 | 52.2% | 76.8% | ||
| Q1 24 | 52.4% | 76.4% |
| Q4 25 | 19.4% | 3.3% | ||
| Q3 25 | 13.2% | -1.5% | ||
| Q2 25 | 24.2% | -10.3% | ||
| Q1 25 | 21.9% | -12.0% | ||
| Q4 24 | 24.2% | -6.7% | ||
| Q3 24 | 29.8% | -11.7% | ||
| Q2 24 | 30.3% | -13.0% | ||
| Q1 24 | 27.9% | -10.4% |
| Q4 25 | 13.3% | 4.9% | ||
| Q3 25 | 9.0% | 1.2% | ||
| Q2 25 | 17.8% | -9.0% | ||
| Q1 25 | 14.8% | -10.4% | ||
| Q4 24 | 20.4% | -4.4% | ||
| Q3 24 | 21.1% | -9.2% | ||
| Q2 24 | 20.8% | -9.9% | ||
| Q1 24 | 25.1% | -6.7% |
| Q4 25 | $0.51 | $0.21 | ||
| Q3 25 | $0.37 | $0.05 | ||
| Q2 25 | $0.64 | $-0.35 | ||
| Q1 25 | $0.51 | $-0.38 | ||
| Q4 24 | $0.74 | $-0.15 | ||
| Q3 24 | $0.78 | $-0.31 | ||
| Q2 24 | $0.73 | $-0.32 | ||
| Q1 24 | $0.81 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $338.8M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $-5.4M |
| Total Assets | $1.6B | $1.5B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $338.8M | ||
| Q3 25 | $276.2M | $315.9M | ||
| Q2 25 | $231.8M | $284.3M | ||
| Q1 25 | $236.9M | $242.0M | ||
| Q4 24 | $221.6M | $301.8M | ||
| Q3 24 | $250.5M | $248.2M | ||
| Q2 24 | $217.8M | $267.9M | ||
| Q1 24 | $289.6M | $296.1M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $-5.4M | ||
| Q3 25 | $776.7M | $-36.9M | ||
| Q2 25 | $757.5M | $-66.5M | ||
| Q1 25 | $751.3M | $-75.7M | ||
| Q4 24 | $732.3M | $-41.7M | ||
| Q3 24 | $727.7M | $-50.8M | ||
| Q2 24 | $713.3M | $-77.7M | ||
| Q1 24 | $672.4M | $-83.2M |
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.6B | $1.2B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $51.0M |
| Free Cash FlowOCF − Capex | $24.6M | $50.7M |
| FCF MarginFCF / Revenue | 13.4% | 21.2% |
| Capex IntensityCapex / Revenue | 4.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.35× | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $138.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $51.0M | ||
| Q3 25 | $52.6M | $46.2M | ||
| Q2 25 | $35.6M | $50.3M | ||
| Q1 25 | $35.1M | $-7.4M | ||
| Q4 24 | $29.0M | $44.0M | ||
| Q3 24 | $60.0M | $18.9M | ||
| Q2 24 | $69.1M | $-14.0K | ||
| Q1 24 | $55.3M | $24.8M |
| Q4 25 | $24.6M | $50.7M | ||
| Q3 25 | $47.2M | $46.1M | ||
| Q2 25 | $25.0M | $49.3M | ||
| Q1 25 | $24.4M | $-8.1M | ||
| Q4 24 | $16.6M | $43.2M | ||
| Q3 24 | $46.2M | $18.7M | ||
| Q2 24 | $63.1M | $-122.0K | ||
| Q1 24 | $46.5M | $24.6M |
| Q4 25 | 13.4% | 21.2% | ||
| Q3 25 | 24.6% | 20.5% | ||
| Q2 25 | 14.3% | 22.9% | ||
| Q1 25 | 14.3% | -3.9% | ||
| Q4 24 | 8.9% | 21.6% | ||
| Q3 24 | 24.1% | 10.1% | ||
| Q2 24 | 34.6% | -0.1% | ||
| Q1 24 | 27.1% | 14.0% |
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.5% | ||
| Q1 25 | 6.3% | 0.4% | ||
| Q4 24 | 6.7% | 0.4% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 0.1% |
| Q4 25 | 1.35× | 4.31× | ||
| Q3 25 | 3.03× | 16.57× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
WK
| License And Service | $219.3M | 92% |
| XBRL Professional Services | $16.4M | 7% |
| Other Services | $3.2M | 1% |
